Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants

CD47 transduces inhibitory signals through signal-regulatory protein α (SIRPα), a plasma membrane receptor expressed by macrophages. Many cancers upregulate CD47 to evade immunosurveillance. We have recently engineered SIRPα variants that potently antagonize CD47 for use as anticancer immunotherapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiskopf, Kipp, Ring, Aaron M, Schnorr, Peter J, Volkmer, Jens-Peter, Volkmer, Anne Kathrin, Weissman, Irving L, Garcia, K Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850276/
https://www.ncbi.nlm.nih.gov/pubmed/24319639
http://dx.doi.org/10.4161/onci.25773
Descripción
Sumario:CD47 transduces inhibitory signals through signal-regulatory protein α (SIRPα), a plasma membrane receptor expressed by macrophages. Many cancers upregulate CD47 to evade immunosurveillance. We have recently engineered SIRPα variants that potently antagonize CD47 for use as anticancer immunotherapeutics. These high-affinity SIRPα variants synergize with antineoplastic antibodies by lowering the threshold for macrophage-mediated destruction of malignant cells.

Ejemplares similares